Benzinga | Nov 4, 2020 10:38AM EST

Rocket Pharma To Present Data From Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency Programs At American Society Of Hematology Meeting Dec. 7

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces presentations at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting being held virtually December 5-8, 2020. There will be two oral presentations highlighting clinical data from the Fanconi Anemia (FA) and Leukocyte Adhesion Deficiency-I (LAD-I) programs as well as a poster presentation highlighting preliminary clinical data from the Pyruvate Kinase Deficiency (PKD) program. All three programs utilize Rocket's "Process B" manufacturing platform.

Details for Rocket's presentations are as follows:

Oral Presentations

Title: Gene Therapy for Fanconi Anemia, Complementation Group A: Updated Results from Ongoing Global Clinical Studies of RP-L102

Session Title: Gene Editing, Therapy and Transfer I

Presenter: Agnieszka Czechowicz, M.D., Ph.D., Assistant Professor of Pediatrics, Division of Stem Cell Transplantation, Stanford University School of Medicine

Session Date: Monday, December 7, 2020

Session Time: 11:30 a.m. - 1:00 p.m. (Pacific Time)

Presentation Time: 12:15 p.m. (Pacific Time)

Title: Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from Phase 1

Session Title: Gene Editing, Therapy and Transfer I

Presenter: Donald Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles

Session Date: Monday, December 7, 2020

Session Time: 11:30 a.m. - 1:00 p.m. (Pacific Time)

Presentation Time: 12:30 p.m. (Pacific Time)

Poster Presentation

Title: Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Session Title: Gene Editing, Therapy and Transfer: Poster II

Presenter: Jos? Luis L?pez Lorenzo, M.D., Hospital Universitario Fundaci?n Jim?nez D?az, Madrid, Spain

Session Date: Sunday, December 6, 2020

Session Time: 7:00 a.m. -- 3:30 p.m. (Pacific Time)